Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Clinical Performance and Quality Measures for Adults With Acute ST-Elevation Myocardial Infarction in China

8. oktober 2019 opdateret af: China National Center for Cardiovascular Diseases
This study aims to investigate and evaluate clinical performance and quality measures for adults with acute ST-elevation myocardial infarction (STEMI) in China. Further more, the investigates like to develop quality improvement strategies and relevant tools focusing on treatment and clinical outcome in patients with STEMI. This is a annually survey , through consecutively recruiting all eligible inpatients and collecting relevant medical information, the performance of all participating hospitals. Further, quality improvement strategies including summary of clinical performance and quality measures, clinical pathways and team building will be organized for the purpose of quality improvement. All hospitals will consecutively recruit qualified patients in the same method adopted in baseline period. Then the reperfusion rates and other performance measures will be compared annually.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Cardiovascular disease (CVD) is a major concern in public health globally, as well as in China, and remarkable variations of resources available and health system performance have been noted. Acute myocardial infarction is one of the leading causes of mortality and morbidity, both in rural and urban area.

This study aims to investigate and evaluate clinical performance and quality measures for adults with acute ST-elevation myocardial infarction (STEMI) in China. Further more, the investigates like to develop quality improvement strategies and relevant tools focusing on treatment and clinical outcome in patients with STEMI.

This is a annually survey , through consecutively recruiting all eligible inpatients and collecting relevant medical information, the performance of all participating hospitals. Demographic characteristics, clinical features, diagnostic tests, medications, procedures, and in-hospital outcomes of patients will be obtained and then, the treatment pattern and outcomes will be evaluated. Further, quality improvement strategies including summary of clinical performance and quality measures, clinical pathways and professional training will be organized for the purpose of quality improvement. All hospitals will consecutively recruit qualified patients in the same method adopted in baseline period. Then the reperfusion rates and other performance measures will be compared annually.

New knowledge will be generated about STEMI management in China, to improve STEMI patients prognosis in future.

Undersøgelsestype

Observationel

Tilmelding (Forventet)

200000

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

  • Kina
    • Beijing
      • Beijing, Beijing, Kina, 100037
        • Rekruttering
        • Hongjian Wang
        • Kontakt:
        • Kontakt:
          • Yin Dong
          • Telefonnummer: 13552582795

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Sandsynlighedsprøve

Studiebefolkning

Patients with STEMI who arrive at the hospital within 48 hours from the symptoms onset

Beskrivelse

Inclusion Criteria:

  • Patients with STEMI who arrive at the hospital within 48 hours from the symptoms onset.

Exclusion Criteria:

  • None

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: Kun etui
  • Tidsperspektiver: Tilbagevirkende kraft

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
All hospitals

All hospitals will take the treatment quality improvement strategies and tools into implementation.

Intervention: Behavioral: Quality improvement strategies and tools
Adfærdsmæssigt: Quality improvement strategies and tools
Quality improvement strategies and tools

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Aspirin at arrival
Tidsramme: 24 hours after admission
Proportion of aspirin use within 24 hours of admission among eligible patients
24 hours after admission
Clopidogrel (or ticagrelor) at arrival
Tidsramme: 24 hours after admission
Proportion of Clopidogrel (or ticagrelor) use within 24 hours of admission among eligible patients
24 hours after admission
β-blockers at arrival
Tidsramme: 24 hours after admission
Proportion of β-blockers use within 24 hours of admission among eligible patients
24 hours after admission
ECG at arrival
Tidsramme: 24 hours after admission
Proportion of ECG test within 10 minutes of admission among eligible patients
24 hours after admission
Reperfusionsbehandlingshastighed
Tidsramme: 24 timer efter indlæggelsen
Reperfusionsbehandlingshastighed er defineret som udnyttelsesgrad af trombolytisk terapi eller primær PCI-behandling blandt patienter, der er indiceret med reperfusionsterapi.
24 timer efter indlæggelsen
Time delay from failure of fibrinolysis to angiography(The time from start of fibrinolysis to evaluation of its efficacy is 60-90min)
Tidsramme: 10 days on average (during hospitalization)
The proportion of failure of fibrinolysis to balloon within 90 minutes among all patients receiving PCI.
10 days on average (during hospitalization)
Time delay from start of fibrinolysis to angiography(if fibrinolysis is successful)
Tidsramme: 10 days on average (during hospitalization)
The proportion of from fibrinolysis to balloon (if fibrinolysis is successful) within 2-24hours among all patients receiving PCI.
10 days on average (during hospitalization)
Aktualitet af trombolytisk terapi
Tidsramme: 24 timer efter indlæggelsen
Andelen af ​​dør-til-nål-tid (D2N) inden for 30 minutter blandt alle patienter, der får fibrinolytisk behandling.
24 timer efter indlæggelsen
Timeliness of primary PCI
Tidsramme: 24 hours after admission
The proportion of door to balloon (D2B) within 90 minutes among all patients receiving primary PCI.
24 hours after admission
Door-in-Door-Out Time
Tidsramme: 24 hours after admission
Percentage of patients whose median time from the emergency department arrival at STEMI referral facility to emergency department discharge from STEMI referral facility is equal or less than 30 min. discharge from STEMI referral facility is 30 min.
24 hours after admission
Time to Primary PCI Among Transferred Patients
Tidsramme: 24 hours after admission
Percentage of patients whose median time from first medical contact (at or before emergency department arrival to the STEMI referral facility [e.g., non-PCI-capable facility]) to primary PCI at the STEMI receiving facility (PCI-capable facility) is equal or less than 120 min
24 hours after admission
Evaluation of LDL-C
Tidsramme: 10 days on average (during hospitalization)
Percentage of patients with documentation in the hospital record that LDL-C is evaluated during hospitalization
10 days on average (during hospitalization)
Evaluation of left ventricular ejection fraction
Tidsramme: 10 days on average (during hospitalization)
Percentage of patients with documentation in the hospital record that left ventricular ejection fraction is evaluated during hospitalization
10 days on average (during hospitalization)
Aspirin use during hospitalization
Tidsramme: 10 days on average (during hospitalization)
Proportion of Aspirin use during hospitalization among eligible patients.
10 days on average (during hospitalization)
Clopidogrel (or ticagrelor) use during hospitalization
Tidsramme: 10 days on average (during hospitalization)
Proportion of Clopidogrel (or ticagrelor) use during hospitalization among eligible patients.
10 days on average (during hospitalization)
Brug af β-blokkere under indlæggelse
Tidsramme: 10 dage i gennemsnit (under indlæggelse)
Andel af β-blokkere, der anvendes under indlæggelse blandt kvalificerede patienter.
10 dage i gennemsnit (under indlæggelse)
Angiotensin-converting enzyme inhibitor /angiotensin II receptor blocker use during hospitalization
Tidsramme: 10 days on average (during hospitalization)
Proportion of Angiotensin-converting enzyme inhibitor /angiotensin II receptor blocker use during hospitalization among eligible patients.
10 days on average (during hospitalization)
Statiner bruges under indlæggelse
Tidsramme: 10 dage i gennemsnit (under indlæggelse)
Andel af statiner, der bruges under indlæggelse blandt kvalificerede patienter.
10 dage i gennemsnit (under indlæggelse)
Aspirinbrug ved udskrivelse
Tidsramme: 10 dage i gennemsnit (under indlæggelse)
Andel af aspirinbrug ved udskrivelse blandt kvalificerede patienter.
10 dage i gennemsnit (under indlæggelse)
Clopidogrel (eller ticagrelor) anvendes ved udskrivelse
Tidsramme: 10 dage i gennemsnit (under indlæggelse)
Andel af Clopidogrel (eller ticagrelor) brug ved udskrivelse blandt kvalificerede patienter.
10 dage i gennemsnit (under indlæggelse)
β-blokkere anvendes ved udskrivelse
Tidsramme: 10 dage i gennemsnit (under indlæggelse)
Andel af β-blokkere, der anvendes ved udskrivelse blandt kvalificerede patienter.
10 dage i gennemsnit (under indlæggelse)
angiotensin-converting enzyme inhibitor /angiotensin II receptor blocker use at discharge
Tidsramme: 10 days on average (during hospitalization)
Proportion of angiotensin-converting enzyme inhibitor /angiotensin II receptor blocker use at discharge among eligible patients.
10 days on average (during hospitalization)
Statiner bruges ved udskrivelse
Tidsramme: 10 dage i gennemsnit (under indlæggelse)
Andel af statiner, der bruges ved udskrivelsen blandt kvalificerede patienter.
10 dage i gennemsnit (under indlæggelse)
Aldosterone Antagonist at Discharge
Tidsramme: 10 days on average (during hospitalization)
Proportion of Aldosterone Antagonist use at discharge among eligible patients.
10 days on average (during hospitalization)
Smoking cessation advice/ counseling at Discharge
Tidsramme: 10 days on average (during hospitalization)
Proportion of patients received smoking cessation advice/ counseling
10 days on average (during hospitalization)
all-cause mortality during hospitalization
Tidsramme: 10 days on average (during hospitalization)
Proportion of patients who were all-cause death during hospitalization
10 days on average (during hospitalization)
Cardiac mortality during hospitalization
Tidsramme: 10 days on average (during hospitalization)
Proportion of patients who were cardiac death during hospitalization
10 days on average (during hospitalization)
30-day all-cause mortality
Tidsramme: From admission to 30days
Proportion of patients who were all-cause death from admission to 30days
From admission to 30days
30-day cardiac mortality
Tidsramme: From admission to 30days
Proportion of patients who were cardiac death from admission to 30days
From admission to 30days
30-day readmission rates
Tidsramme: From hospital discharge to 30 days
Proportion of patients readmission from hospital discharge to 30days
From hospital discharge to 30 days
Cost during hospitalization
Tidsramme: 10 days on average (during hospitalization)
Cost during hospitalization
10 days on average (during hospitalization)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

China National Center for Cardiovascular Diseases

Efterforskere

  • Ledende efterforsker: Zhe Zheng, Fuwai Hospital

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

15. juli 2018

Primær færdiggørelse (Forventet)

31. december 2035

Studieafslutning (Forventet)

31. december 2035

Datoer for studieregistrering

Først indsendt

9. september 2019

Først indsendt, der opfyldte QC-kriterier

12. september 2019

Først opslået (Faktiske)

13. september 2019

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. oktober 2019

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

8. oktober 2019

Sidst verificeret

1. september 2019

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • NCCQI-CAD

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med ST Elevation Myokardieinfarkt

Kliniske forsøg med Quality improvement strategies and tools

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Azerbaijan

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner